NasdaqGS:RVMDBiotechs
A Look At Revolution Medicines (RVMD) Valuation After Starting Pivotal Phase 3 RASolute 303 Trial
Revolution Medicines (RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of its RAS inhibitor daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma, spotlighting a key late stage pipeline milestone.
See our latest analysis for Revolution Medicines.
That trial milestone comes after a strong run in the stock, with a 90 day share price return of 26.54% and a one year total shareholder return of 216.48%, pointing to strong momentum around the...